Core Viewpoint - A class action securities lawsuit has been filed against ICON Public Limited Company, alleging securities fraud that negatively impacted investors between July 27, 2023, and October 23, 2024 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that ICON suffered a material loss of business due to customer cost reduction measures and funding limitations affecting its client base [2]. - It is alleged that ICON's service offerings were inadequate to protect the company from a significant market downturn [2]. - The requests for proposals from biotechnology customers were reportedly used as price discovery tools, not reflecting actual client demand [2]. - Customers of ICON are said to have canceled contracts, limited engagements, and delayed clinical trial work, failing to enter new contracts at historical rates [2]. - The two largest customers of ICON were diversifying their clinical research organization providers away from the company [2]. - As a result of these issues, ICON's reported business metrics misrepresented actual client demand for its services [2]. - The company was tracking significantly below its 2024 revenue and EPS guidance, which lacked a reasonable factual basis [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the relevant time frame have until April 11, 2025, to request appointment as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - The ICON PLC class action lawsuit alleges that the company and its executives made misleading statements regarding its business performance and failed to disclose significant operational challenges, leading to substantial financial losses for investors during the specified class period [1][2][3]. Group 1: Allegations Against ICON - The lawsuit claims that ICON suffered a material loss of business due to customer cost reduction measures and funding limitations impacting its client base [2]. - It is alleged that ICON's Functional Service Provision (FSP) and hybrid model offerings were inadequate to mitigate the effects of a market downturn [2]. - The requests for proposals from biotechnology customers were reportedly used as price discovery tools rather than indicative of actual client demand [2]. - Customers canceled contracts, limited engagements, and delayed clinical trial work, which negatively affected ICON's business [2]. - Two of ICON's largest customers were diversifying their CRO providers away from ICON, further impacting its business [2]. - As a result of these issues, ICON's reported net new business awards and book-to-bill metrics misrepresented actual client demand [2]. - Consequently, ICON was tracking significantly below its 2024 revenue and EPS guidance, which lacked a reasonable factual basis [2]. Group 2: Financial Performance - On October 23, 2024, ICON reported quarterly revenues of $2.03 billion, missing consensus estimates of $2.13 billion by over $100 million [3]. - The company's net new business wins declined sequentially to $2.3 billion from $2.6 billion in the prior quarter [3]. - ICON's book-to-bill ratio fell to 1.15 from 1.22 in the previous quarter, indicating a decline in business performance [3]. - Following the announcement of these results, ICON's share price dropped by more than 20% over two trading sessions [3]. Group 3: Legal Process and Representation - Investors who purchased ICON shares during the class period can seek appointment as lead plaintiff in the class action lawsuit [5]. - The lead plaintiff is typically the investor with the greatest financial interest in the case and acts on behalf of all class members [5]. - Robbins Geller Rudman & Dowd LLP, the law firm representing the plaintiffs, has a strong track record in prosecuting investor class actions and has recovered significant monetary relief for investors [6][7].

Core Viewpoint - A class action securities lawsuit has been filed against ICON Public Limited Company, alleging securities fraud that negatively impacted investors between July 27, 2023, and October 23, 2024 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that ICON suffered a significant loss of business due to customer cost reduction measures and funding limitations affecting its client base [2]. - It is alleged that ICON's service offerings were inadequate to protect the company from a major market downturn [2]. - The requests for proposals from biotechnology customers were reportedly used primarily for price discovery, not reflecting actual client demand [2]. - Customers of ICON are said to have canceled contracts, reduced engagements, and delayed clinical trial work, leading to a decline in new contracts at historical rates [2]. - The two largest customers of ICON were diversifying their clinical research organization providers away from the company [2]. - As a result of these issues, ICON's reported business metrics misrepresented actual client demand for its services [2]. - Consequently, ICON was tracking significantly below its 2024 revenue and EPS guidance, which lacked a reasonable factual basis [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified period have until April 11, 2025, to request to be appointed as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing substantial settlements for shareholders and has been recognized as a leading firm in securities litigation [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of ICON Public Limited Company regarding a class action lawsuit due to alleged misleading statements and failure to disclose material information during the class period from July 27, 2023, to October 23, 2024 [1]. Allegations Summary - ICON is accused of suffering a material loss of business due to customer cost reduction measures and funding limitations impacting its client base [1]. - The company's functional service provision and hybrid model offerings were deemed insufficient to protect against a significant market downturn [1]. - Requests for proposals from biotechnology customers were primarily used for price discovery, not indicative of actual client demand [1]. - Customers canceled contracts, limited engagements, delayed clinical trial work, and failed to enter new contracts at historical rates [1]. - ICON's two largest customers were diversifying their clinical research organization providers away from the company [1]. - As a result of the above issues, ICON's reported net new business awards and book-to-bill metrics misrepresented actual client demand [1]. - Consequently, ICON was tracking significantly below the 2024 revenue and EPS guidance issued during the class period, which lacked a reasonable factual basis [1]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by April 11, 2025, to participate in the case without any cost or obligation [2]. - Registered shareholders will be enrolled in a portfolio monitoring software for status updates throughout the case lifecycle [2]. Firm's Mission - The Gross Law Firm aims to protect the rights of investors affected by deceit, fraud, and illegal business practices, ensuring companies adhere to responsible business practices [3].

Core Viewpoint - A class action has been filed against ICON PLC, alleging that the company misled investors regarding its business performance and client demand during the specified period [1][2]. Allegations - ICON PLC experienced a material loss of business due to customer cost reduction measures and funding limitations affecting its client base [1]. - The company's FSP and hybrid model offerings were insufficient to mitigate the adverse effects of a significant market downturn [1]. - Requests for proposals (RFPs) from biotechnology customers were primarily used for price discovery and did not reflect actual client demand [1]. - Customers canceled contracts, reduced engagements, delayed clinical trial work, and failed to enter into new contracts at historical rates [1]. - ICON's two largest customers were diversifying their CRO providers away from the company [1]. - As a result of the above factors, ICON's reported net new business awards and book-to-bill metrics misrepresented actual client demand [1]. - Consequently, ICON was tracking significantly below its 2024 revenue and EPS guidance, which lacked a reasonable factual basis [1]. Impact on Stock Price - Following the revelation of these issues, ICON's stock price dropped significantly, resulting in harm to investors [2]. Class Action Participation - Shareholders may be eligible to participate in the class action against ICON PLC, with a deadline to file as lead plaintiff by April 11, 2025 [3].

NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of ICON plc (NASDAQ: ICLR) between July 27, 2023 and October 23, 2024, both dates inclusive (the “Class Period”), of the important April 11, 2025 lead plaintiff deadline. SO WHAT: If you purchased ICON ordinary shares during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT ...

RADNOR, Pa., March 26, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against ICON Public Limited Company ("ICON") (NASDAQ: ICLR) on behalf of all purchasers of ICON ordinary shares between July 27, 2023 and October 23, 2024, inclusive (the "Class Period"). The lead plaintiff deadline is April 11, 2025.CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:If you suffered ICON losses, you may CLICK HERE or co ...

Core Viewpoint - ICON Public Limited Company (NASDAQ: ICLR) is facing allegations of issuing materially false and misleading statements during the class period from July 27, 2023, to October 23, 2024, which has led to significant business losses and misrepresentation of client demand [3][4]. Group 1: Allegations Against ICON - The complaint alleges that ICON suffered a material loss of business due to customer cost reduction measures and funding limitations impacting its client base [3]. - ICON's functional service provision and hybrid model offerings were insufficient to protect the company from a significant market downturn [3]. - Requests for proposals from biotechnology customers were primarily used as price discovery tools, not indicative of actual client demand [3]. - Customers canceled contracts, limited engagements, delayed clinical trial work, and failed to enter into new contracts at historical rates [3]. - ICON's two largest customers were diversifying their clinical research organization providers away from the company [3]. - As a result of the above factors, ICON's reported net new business awards and book-to-bill metrics materially misrepresented client demand for its services [3]. - Consequently, ICON was tracking materially below the 2024 revenue and EPS guidance issued during the class period, which lacked a reasonable factual basis [3]. Group 2: Class Action Details - Shareholders who purchased shares of ICLR during the class period are encouraged to contact the Gross Law Firm for possible lead plaintiff appointment [1][4]. - The deadline for shareholders to register for the class action is April 11, 2025 [4]. - Once registered, shareholders will be enrolled in a portfolio monitoring software for status updates throughout the case lifecycle [4].

Core Viewpoint - ICON PLC is facing a class action lawsuit due to alleged misleading statements and undisclosed issues that have materially affected its business performance during the specified class period [3][4]. Group 1: Class Action Details - The class action lawsuit represents investors who purchased ICON securities between July 27, 2023, and October 23, 2024, with a deadline of April 11, 2025, for filing a lead plaintiff motion [1]. - Investors are encouraged to contact the Portnoy Law Firm for a complimentary case evaluation regarding their legal rights and options for recovering losses [2]. Group 2: Business Performance Issues - ICON has reportedly suffered significant business losses due to customer cost-cutting measures and broader funding constraints, which have impacted its client base [3]. - The company's claims regarding its Functional Service Provision (FSP) and hybrid model offerings were found to be inadequate, as many biotechnology customers used ICON's proposals primarily for price discovery rather than actual demand [3][4]. - Major clients canceled contracts and reduced clinical trial work, leading to a decline in new agreements and a misrepresentation of actual client demand in ICON's reported metrics [4]. Group 3: Financial Results and Market Reaction - On October 23, 2024, ICON reported third-quarter revenue of $2.03 billion, which was over $100 million below consensus estimates, alongside a decline in net new business wins and a drop in the book-to-bill ratio [5]. - CEO Stephen Cutler acknowledged that two major pharmaceutical customers had significantly reduced FSP trial work due to ongoing cost containment measures, which would continue to negatively impact financial performance [5]. - Following the financial results announcement, ICON's stock price dropped more than 20% over two trading sessions [5].

SAN DIEGO, March 24, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers of ICON PLC (NASDAQ: ICLR) ordinary shares between July 27, 2023 and October 23, 2024, both dates inclusive (the "Class Period"), have until Friday, April 11, 2025 to seek appointment as lead plaintiff of the ICON class action lawsuit. Captioned Shing v. ICON plc, No. 25-cv-00763 (E.D.N.Y.), the ICON class action lawsuit charges ICON as well as certain of ICON's top executive officers with violations of the ...